Explore the Global SGLT2 Inhibitors Market— analysis of key trends, regional growth, top players, and a 10-year forecast from 2026 to 2036.

Future Market Insights

SGLT2 Inhibitors Market

Key Insight

The SGLT2 Inhibitors market was valued at USD 17.8 billion in 2025. Demand is expected to grow at USD 18.9 billion in 2026 and USD 34.5 billion by 2036. Jardiance (empagliflozin) is expected to lead with 55.3% share by drug segment in 2026 and Type 2 Diabetes is estimated to lead indication segment with 71.8% share in 2026.

February 19, 2026

Anurag Sharma

250 Pages

Cite this Report

SGLT2 Inhibitors Market

https://www.futuremarketinsights.com/reports/sglt2-inhibitors-market

License

Buy Now

Summary ToC Companies

Key Players

BlackRock
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb
Eli Lilly and Company
Glenmark Pharmaceuticals
Johnson & Johnson Services
Lexicon Pharmaceuticals
Merck KGaA
TheracosBio

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

SGLT2 Inhibitors Market

Key Players

Similar Industry Reports